Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?
Novo Nordisk's Wegovy pill is outperforming early expectations, with prescriptions rising fast and possibly broadening the GLP-1 market.
Intelligence analysis by GPT-5.4 Mini
The article argues Novo Nordisk's new Wegovy pill is doing better than expected and may widen the GLP-1 market instead of just shifting demand from the shot. That could support the stock, even as 2026 brings patent loss in India and U.S. price cuts.
Novo Nordisk made a weight-loss pill that is selling faster than expected, like a new snack that people grab instead of the old one. The company still has problems, but the pill could help it catch up after falling behind rival Eli Lilly.
Analysis
Novo's turnaround story
Novo Nordisk lost momentum after being first to market with a GLP-1 weight-loss drug but failing to meet demand for Wegovy shots. That opened the door for compounders in the U.S. and gave Eli Lilly room to pull ahead with Mounjaro and Zepbound, helped by stronger efficacy and better investor sentiment.
Why the pill matters
The new Wegovy pill, launched at the start of 2026, appears to be changing the picture. The article says many consumers prefer pills over injections, and the early prescription data suggests the market may be expanding rather than simply shifting from shot to pill. Novo reported 1.3 million prescriptions in the first quarter, then said that figure had climbed to two million by its first-quarter earnings update one month later.
The investment case
Novo still has a difficult year ahead. The article says Wegovy is losing patent protection in India, which will pressure sales there, and the company has also agreed to cut U.S. prices. Management expects higher volume to offset lower prices over time, and the early demand for the pill makes that argument look more credible.
The risk and the reward
The healthcare sector remains intensely competitive, and Eli Lilly also has a GLP-1 pill, even if it is a different drug from its shot. Still, the article argues Novo's pill appears more effective and may give the company a marketing edge. For dividend-focused investors, the piece points to Novo's roughly 3.9% yield and about 40% payout ratio as reasons the stock may be attractive while investors wait for the turnaround to develop.
Key points
- Novo Nordisk lost ground after supply problems with Wegovy shots opened the door for Eli Lilly and compounders.
- The new Wegovy pill is selling faster than expected, with prescriptions rising from 1.3 million to two million in a short period.
- The article argues the pill may be expanding the GLP-1 market instead of cannibalizing the shot.
- Novo still faces pressure from patent loss in India and lower U.S. pricing.
- Dividend investors may find the stock appealing because of its relatively high yield and reasonable payout ratio.
If Wegovy pills keep winning prescriptions, Novo Nordisk could grow by reaching people who prefer pills over shots. The article says volume may offset price pressure over time, and the stock also offers a relatively high dividend while investors wait.
Novo Nordisk still faces a tough 2026 because Wegovy is losing patent protection in India and the company has agreed to lower U.S. prices. Competition is also intense, and Eli Lilly already has stronger momentum in the GLP-1 market.
